drugset / Trial / NCT01202097

A Non- Inferiority Comparative Study Between Seretide® and Salmeterol/Fluticasone Eurofarma in Patients with Asthma

NCT01202097 ↗

Phase 3 Completed 334 enrolled Eurofarma Laboratorios S.A.
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective will be to compare the formulations regarding their impact on the pulmonary function of persistent asthma patients and the secondary objective will be the clinical control of the disease's symptoms.

Timeline

Start
2011-08
Primary completion
—
Completion
2012-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Salmeterol/Fluticasone Unknown 50 ug Inhaled
Comparator Salmeterol/Fluticasone Unknown 50 ug Inhaled
Subject Salmeterol/Fluticasone Unknown 250 ug Inhaled
Comparator Salmeterol/Fluticasone Unknown 250 ug Inhaled

Indications